Form 4: Elicio Therapeutics Director Julian Adams Acquires Stock Options

Director Julian Adams of Elicio Therapeutics acquired 4,100 stock options on November 21, 2024, which will vest on the earlier of November 21, 2025, or the next annual meeting.

Summary

• Julian Adams, a director at Elicio Therapeutics, was granted 4,100 stock options on November 21, 2024.
• The exercise price of these options is $5.12 per share.
• The options will vest and become exercisable on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date.
• The vesting is contingent upon Mr. Adams continuing to provide services to the company through the vesting date.
• The options expire on November 21, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to directors, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The stock options will vest based on continued service and the timing of the next annual meeting.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize directors and align their interests with shareholders.
• The vesting period of one year or the next annual meeting is typical for such grants.
• The exercise price of $5.12 is specific to Elicio Therapeutics and its current valuation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and performance.

Next Steps

• The stock options will vest upon the earlier of November 21, 2025, or the next annual meeting of the company's stockholders, provided Mr. Adams continues to provide services to the company.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, equity, vesting, insider trading, ELTX